Sophia Randolph - Sep 10, 2021 Form 4 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)

Role
Chief Medical Officer, Director
Signature
/s/ Peter Garcia, by power of attorney
Stock symbol
ALXO
Transactions as of
Sep 10, 2021
Transactions value $
-$573,670
Form type
4
Date filed
9/13/2021, 07:10 PM
Previous filing
Aug 11, 2021
Next filing
Oct 12, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALXO Common Stock Sale -$68.8K -900 -0.55% $76.45* 163K Sep 10, 2021 Direct F1, F2
transaction ALXO Common Stock Sale -$391K -5.03K -3.08% $77.69* 158K Sep 10, 2021 Direct F1, F3
transaction ALXO Common Stock Sale -$114K -1.46K -0.92% $78.31* 157K Sep 10, 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.03 to $76.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.07 to $78.06, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.07 to $78.86, inclusive.